

Nabil William Sweis
34 posts

@Sweis_NWG
Research @NU_Nephrology | 2024 M.D. Graduate @UJ_MED 🩺 | Aspiring internist, researcher & educator | Medical illustrator @COREIMpodcast | Piano enthusiast 🎶



This #ASNKidney360 study explored the relationship between arterial and venous blood gas parameters to develop formulas for estimating arterial values from venous samples. Read more: kidney.pub/KID1113



1/ 🚨NEW: In the Nick of Time - What’s with this IV?? 5 factors in choosing an IV 💥 💧Length 💧Width 💧Lumens 💧Time 💧Contraindications 🎥:coreimpodcast.com/2026/02/04/whi…


1/🚨NEW: Let’s demystify cholecystostomy tube and biliary drains! 😶🌫️ Ever thought when to consult IR to place a drain? 🤔 Find out here! 👀 🎥:coreimpodcast.com/2026/01/14/cho… 🖥️:youtube.com/watch?v=Rl1C78…



1/ 🚨New 5 Pearls 🚨 Severe Hypertriglyceridemia @NatTgAlliance How quickly can triglycerides rise? At what threshold are patients at risk of pancreatitis? or cardiovascular adverse outcomes?



ASN Kidney News Oct-Nov 2025 @asnpublications kidneynews.org/view/journals/… Renal Tubular Alkalosis: A Novel Renal Syndrome? Nabil William G. Sweis and Daniel Batlle






Check out our recent analysis @OncJournal under mentorship of @ADesaiMD of 653 solid tumors evaluating HER2 by IHC, CNV & mutational profiling. 📊 Results: •IHC+: 3+ (3.1%), 2+ (13.2%), 1+ (19.8%), 63.9% neg •CN amplification: 3.1% (75% IHC3+) •Pathogenic ERBB2 mutations: 3.1% (only 5% IHC3+) 🔑 ERBB2-mut tumors rarely show IHC3+/CN amp → highlights need for comprehensive genomic testing. 💡 In the era of pan-tumor T-DXd approval, integrating genomic + phenotypic data can refine patient selection & advance precision oncology. @ONealCancerUAB @MehmetAkce2 @YanisBoumberMD @BasselElRayesMD @SylvesterCancer @HemOncMiami @carisls











@ConnieMRhee @CJASN Thank you Connie for your kind comment on our CJASN review paper on DRTA treatment by Elba Medina @elbaonelida and Gema Ariceta. Thanks also to @Sweis_NWG for creating this nice figure. @NU_Nephrology pubmed.ncbi.nlm.nih.gov/38967973/
